Современные представления о патогенезе, особенностях клинической картины, диагностике и терапевтической тактике вульгарных акне у детей и подростков
https://doi.org/10.15690/vsp.v19i6.2141
Аннотация
В статье представлены современные данные о патогенезе вульгарных акне (ВА), особенностях клинической картины, диагностике и терапевтической тактике у детей и подростков. Приведены сведения о влиянии наиболее значимых внешних и внутренних факторов на патогенез и риск развития ВА. На основе анализа Европейских методических рекомендаций и рекомендаций Глобального альянса по лечению и диагностике ВА сформированы соответствующие диагностические и терапевтические алгоритмы ведения пациентов. Также продемонстрирована важная роль назначения эффективной терапии в виде фиксированной синергичной комбинации активных веществ, представленных топическим ретиноидом (адапален) и бензоила пероксидом.
Ключевые слова
При поддержке: Статья опубликована при поддержке компании Galderma
Об авторах
Е. Р. Аравийская
Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Россия
Санкт-Петербург
Раскрытие интересов:
Россия
Санкт-Петербург
Раскрытие интересов:
Е. Р. Аравийская — получение гонораров за научное консультирование от компаний Galderma, Pierre Fabre, La Roche Posay, Bioderma, Vichy, Bayer, LEO Pharma, Pfizer, AbbVie, Amryt Pharma, ООО «Зелдис-Фарма»
Н. Н. Мурашкин
НИИ педиатрии и охраны здоровья детей ЦКБ РАН;
Национальный медицинский исследовательский центр здоровья детей;
Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет);
Центральная государственная медицинская Академия Управления делами Президента РФ
Россия
Раскрытие интересов:
Россия
Мурашкин Николай Николаевич, доктор медицинских наук, заведующий отделением дерматологии с группой лазерной хирургии, заведующий лабораторией патологии кожи у детей отдела научных исследований в педиатрии НМИЦ здоровья детей, профессор кафедры дерматовенерологии и косметологии ЦГМА, профессор кафедры педиатрии и детской ревматологии Первого МГМУ им. И.М. Сеченова
119296, Москва, Ломоносовский пр-т, д. 2, стр. 1
Раскрытие интересов:
Н. Н. Мурашкин — получение исследовательских грантов от фармацевтических компаний Jansen, Eli Lilly, Novartis. Получение гонораров за научное консультирование от компаний Galderma, Pierre Fabre, Bayer, LEO Pharma, Pfizer, AbbVie, Amryt Pharma
Л. С. Намазова-Баранова
НИИ педиатрии и охраны здоровья детей ЦКБ РАН;
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова
Россия
Москва
Раскрытие интересов:
Россия
Москва
Раскрытие интересов:
Л. С. Намазова-Баранова — получение исследовательских грантов от фармацевтических компаний Пьер Фабр, Genzyme Europe B. V., ООО «Астра Зенека Фармасьютикалз», Gilead / PRA «Фармасьютикал Рисерч Ассошиэйтс СиАйЭс», Bionorica, Teva Branded Pharma ceuti cal products R&D, Inc / ООО «ППД Девелопмент (Смоленск)», «Сталлержен С. А.» / «Квинтайлс ГезмбХ» (Австрия)
Р. А. Иванов
Национальный медицинский исследовательский центр здоровья детей
Россия
Раскрытие интересов:
Россия
Москва
Раскрытие интересов:
Р.А. Иванов подтвердил отсутствие конфликта интересов, о котором необходимо сообщить
Список литературы
1. Rathi SK. Acne vulgaris treatment: the current scenario. Indian J Dermatol. 2011;56(1):7–13. doi: 10.4103/0019-5154.77543.
2. Sevimli Dikicier B. Topical treatment of acne vulgaris: efficiency, side effects, and adherence rate. J Int Med Res. 2019;47(7): 2987–2992. doi: 10.1177/0300060519847367.
3. Аравийская Е.Р., Соколовский Е.В. Руководство по дерматокосметологии. СПб.: ООО «Издательство ФОЛИАНТ»; 2008. — 632 с.
4. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859): 2163–2196. doi: 10.1016/S0140-6736(12)61729-2.
5. Picardo M, Eichenfield LF, Tan J. Acne and Rosacea. Dermatol Ther (Heidelb). 2017;7(Suppl 1):43–52. doi: 10.1007/s13555-016-0168-8.
6. Ulvestad M, Bjertness E, Dalgard F, Halvorsen JA. Acne and dairy products in adolescence: results from a Norwegian longitudinal study. J Eur Acad Dermatol Venereol. 2016;31(3):530–535. doi: 10.1111/jdv.13835.
7. Wolkenstein P, Misery L, Amici J-M, et al. Smoking and Dietary Factors Associated with Moderate-to-Severe Acne in French Adolescents and Young Adults: Results of a Survey Using a Representative Sample. Dermatology. 2014;230(1):34–39. doi: 10.1159/000366195.
8. Schafer T, Nienhaus A, Vieluf D, et al. Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol. 2001; 145(1):100–104. doi: 10.1046/j.1365-2133.2001.04290.x.
9. Bagatin E, Timpano DL, Guadanhim LR, et al. Acne vulgaris: prevalence and clinical forms in adolescents from Sao Paulo, Brazil. An Bras Dermatol. 2014;89(3):428–435. doi: 10.1590/abd1806-4841.20142100.
10. Nijsten T, Rombouts S, Lambert J. Acne is prevalent but use of its treatments is infrequent among adolescents from the general population. J Eur Acad Dermatol Venereol. 2007;21(2):163–168. doi: 10.1111/j.1468-3083.2006.01829.x.
11. Bhat YJ, Latief I, Hassan I. Update on etiopathogenesis and treatment of Acne. Indian J Dermatol Venereol Leprol. 2017;83(3): 298–306. doi: 10.4103/0378-6323.199581.
12. Tan JKL, Stein Gold LF, Alexis AF, Harper JC. Current Concepts in Acne Pathogenesis: Pathways to Inflammation. Semin Cutan Med Surg. 2018;37(3S):S60–S62. doi: 10.12788/j.sder.2018.024.
13. Taylor M, Gonzalez M, Porter R. Pathways to inflammation: acne pathophysiology. Eur J Dermatol. 2011;21(3):323–333. doi: 10.1684/ejd.2011.1357.
14. Dreno B, Gollnick HPM, Kang S, et al. Understanding innate immunity and inflammation in acne: implications for management. J Eur Acad Dermatol Venereol. 2015;29(Suppl 4):3–11. doi: 10.1111/jdv.13190.
15. Tanghetti EA. The role of inflammation in the pathology of acne. J Clin Aesthet Dermatol. 2013;6(9):27–35.
16. Jeremy AH, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003; 121(1):20–27. doi: 10.1046/j.1523-1747.2003.12321.x.
17. Kistowska M, Gehrke S, Jankovic D, et al. IL-1 Drives Inflammatory Responses to Propionibacterium acnes In Vitro and In Vivo. J Invest Dermatol. 2014;134(3):677–685. doi: 10.1038/jid.2013.438.
18. Contassot E, French LE. New Insights into Acne Pathogenesis: Propionibacterium Acnes Activates the Inflammasome. J Invest Dermatol. 2014;134(2):310–313. doi: 10.1038/jid.2013.505.
19. Coenye T, Peeters E, Nelis HJ. Biofilm formation by Pro pionibacterium acnes is associated with increased resistance to antimicrobial agents and increased production of putative virulence factors. Res Microbiol. 2007;158(4):386–392. doi: 10.1016/j.resmic.2007.02.001.
20. Jahns AC, Lundskog B, Gancevicience R, et al. An increased incidence of Propionibacterium acnes biofilms in acne vulgaris: a case–control study. Clin Lab Invest. 2012;167(1):50–58. doi: 10.1111/j.1365-2133.2012.10897.x.
21. Olson ME, Ceri H, Morck DW, et al. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res. 2002;66(2):86–92.
22. Tyner H, Patel R. Propionibacterium acnes biofilm — A sanctuary for Staphylococcus aureus? Anaerobe. 2016;40:63–67. doi: 10.1016/j.anaerobe.2016.05.014.
23. Burkhart CG, Burkhart CN. Expanding the microcomedone theory and acne therapeutics: Propionibacterium acnes biofilm produces biological glue that holds corneocytes together to form plug. J Am Acad Dermatol. 2007;57(4):722–724. doi: 10.1016/j.jaad.2007.05.013.
24. Kurokawa I, Danby FW, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009;18(10):821–832. doi: 10.1111/j.1600-0625.2009.00890.x.
25. Nakatsuji T, Kao MC, Zhang L, et al. Sebum free fatty acids enchance the innate immune defense of human sebocytes by upregulating beta-defensin-2 expression. J Invest Dermatol. 2010; 130(4):985–994. doi: 10.1038/jid.2009.384.
26. Lwin SM, Kimber I, McFadden JP. Acne, quorum sensing and danger. Clin Exp Dermatol. 2014;39(2):162–167. doi: 10.1111/ced.12252.
27. Rosen J, Friedman A. Inflammatory Acne: New Developments in Pathogenesis and Treatment. Cutis. 2014;94(6):266–267.
28. Linfante A, Allawh RM, Allen HB. The Role of Propionibacterium acnes Biofilm in Acne Vulgaris. J Clin Exp Dermatol Res. 2018; 9(1):1000439. doi: 10.4172/2155-9554.1000439.
29. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010; 11(5):373–384. doi: 10.1038/ni.1863.
30. Eltom S, Belvisi MG, Yew-Booth L, et al. TLR4 activation induces IL-1 release via an IPAF dependent but caspase 1/11/8 independent pathway in the lung. Respir Res. 2014;15(1):87. doi: 10.1186/s12931-014-0087-0.
31. Guy R, Kealey T. The effects of inflammatory cytokines on the isolated human sebaceous infundibulum. J Invest Dermatol. 1998;110(4):410–415. doi: 10.1046/j.1523-1747.1998.00143.x.
32. Selway JL, Kurczab T, Kealey T, Langlands K. Toll-like receptor 2 activation and comedogenesis: Implications for the pathogenesis of acne. BMC Dermatol. 2013;13:10. doi: 10.1186/1471-5945-13-10.
33. Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002;169(3):1535–1541. doi: 10.4049/jimmunol.169.3.1535.
34. El-Komy MHM, Shaker O. IL-18 Expression in Inflammatory Acne Vulgaris: Another Propionibacterium acnes Induced Cytokine? J Egypt wom Dermatol Soc. 2006;3(2):81–85.
35. Sardana K, Verma G. Propionibacterium acnes and the Th1/ Th17 Axis, implications in acne pathogenesis and treatment. Indian J Dermatol. 2017;62(4):392–394. doi: 10.4103/ijd.IJD_483_16.
36. Agak GW, Qin M, Nobe J, et al. Propionibacterium acnes Induces an IL-17 Response in Acne Vulgaris that Is Regulated by Vitamin A and Vitamin D. J Invest Dermatol. 2014;134(2):366–373. doi: 10.1038/jid.2013.334.
37. Masterson KN. Acne Basics: Pathophysiology, Assessment, and Standard Treatment Options. J Dermatol Nurses Assoc. 2018; 10(1S):S2–S10. doi: 10.1097/jdn.0000000000000361.
38. Zaidi Z. Acne vulgaris — an update on pathophysiology and treatment. J Pak Med Assoc. 2009;59(9):635–637.
39. Iftikhar U, Choudhry N. Serum levels of androgens in acne & their role in acne severity. Pak J Med Sci. 2019;35(1):146–150. doi: 10.12669/pjms.35.1.131.
40. Zouboulis CC, Degitz K. Androgen action on human skin: from basic research to clinical significance. Exp Dermatol. 2004;13 (Suppl 4):5–10. doi: 10.1111/j.1600-0625.2004.00255.x.
41. Deplewski D, Rosenfield RL. Role of Hormones in Pilosebaceous Unit Development. Endocr Rev. 2000;21(4):363–392. doi: 10.1210/edrv.21.4.0404.
42. Melnik BC. FoxO1 — the key for the pathogenesis and therapy of acne? J Dtsch Dermatol Ges. 2010;8(2):105–113. doi: 10.1111/j.1610-0387.2009.07344.x.
43. Kim H, Moon SY, Sohn MY, Lee WJ. Insulin-Like Growth Factor-1 Increases the Expression of Inflammatory Biomarkers and Sebum Production in Cultured Sebocytes. Ann Dermatol. 2017;29(1): 20–25. doi: 10.5021/ad.2017.29.1.20.
44. Smith TM, Gilliland K, Clawson GA, Thiboutot D. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol. 2008 May;128(5):1286-93. doi: 10.1038/sj.jid.5701155.
45. Heng AHS, Chew FT. Systematic review of the epidemiology of acne vulgaris. Sci Rep. 2020;10(1):5754. doi: 10.1038/s41598-020-62715-3.
46. Dreno B, Bettoli V, Araviiskaia E, et al. The influence of exposome on acne. J Eur Acad Dermatol Venereol. 2018;32(5):812–819. doi: 10.1111/jdv.14820.
47. Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013;168(3):474–485. doi: 10.1111/bjd.12149.
48. Wolkenstein P, Machovcova A, Szepietowski JC, et al. Acne prevalence and associations with lifestyle: a cross-sectional online survey of adolescents/young adults in 7 European countries. J Eur Acad Dermatol Venereol. 2017;32(2):298–306. doi: 10.1111/jdv.14475.
49. Walton S, Wyatt EH, Cunliffe WJ. Genetic control of sebum excretion and acne—a twin study. Br J Dermatol. 1988;118(3):393–396. doi: 10.1111/j.1365-2133.1988.tb02433.x.
50. Al Hussein SM, Al Hussein H, Vari CE et al. Diet, Smoking and Family History as Potential Risk Factors in Acne Vulgaris — a Community-Based Study. Acta Medica Marisiensis. 2016;62(2): 173–181. doi: 10.1515/amma-2016-0007.
51. Lu LY, Lai HY, Pan ZY,et al. Obese/overweight and the risk of acne vulgaris in Chinese adolescents and young adults. Hong Kong J Dermatol Venereol. 2017;25:5–12.
52. Melnik BC. Linking diet to acne metabolomics, inflammation, and comedogenesis: An update. Clin Cosmet Investig Dermatol. 2015;8:371–388. doi: 10.2147/CCID.S69135.
53. Spencer EH, Ferdowsian HR, Barnard ND. Diet and acne: a review of the evidence. Int J Dermatol. 2009;48(4):339–347. doi: 10.1111/j.1365-4632.2009.04002.x.
54. Belushkin M, Jaccard G, Kondylis A. Considerations for comparative tobacco product assessments based on smoke constituent yields. Regul Toxicol Pharmacol. 2015;73(1):105–113. doi: 10.1016/j.yrtph.2015.06.017.
55. Just M, Ribera M, Monso E, et al. Effect of smoking on skin elastic fibres: morphometric and immunohistochemical analysis. Br J Dermatol. 2007; 156(1): 85–91. doi: 10.1111/j.1365-2133.2006.07575.x.
56. Sticozzi C, Belmonte G, Cervellati F, et al. Resveratrol protects SR-B1 levels in keratinocytes exposed to cigarette smoke. Free Radic Biol Med. 2014;69:50–57. doi: 10.1016/j.freeradbiomed.2014.01.007.
57. Capitanio B, Sinagra JL, Ottaviani M, et al. Acne and smoking. Dermatoendocrinology. 2009;1(3):129–135. doi: 10.4161/derm.1.3.9638.
58. Sardana K, Sharma RC, Sarkar R. Seasonal variation in acne vulgaris — myth or reality. J Dermatol. 2002;29(8):484–488. doi: 10.1111/j.1346-8138.2002.tb00313.x.
59. Gfesser M, Worret WI. Seasonal variations in the severity of acne vulgaris. Int J Dermatol. 1996;35(2):116–117. doi: 10.1111/j.1365-4362.1996.tb03274.x.
60. Plewig G, Kligman AM. Ultraviolet Radiation. Acne and Rosacea. Berlin, Heidelberg, Germany: Springer Verlag; 2000.
61. Lee WJ, Chae SY, Ryu HS, et al. Inflammatory Cytokine Expression and Sebum Production After Exposure of Cultured Human Sebocytes to Ultraviolet A Radiation and Light at Wavelengths of 650 nm and 830 nm. Ann Dermatol. 2015;27(2):163–170. doi: 10.5021/ad.2015.27.2.163
62. Suh DH, Kwon TE, Youn JI. Changes of comedonal cytokines and sebum secretion after UV irradiation in acne patients. Eur J Dermatol. 2002;12(2):139–144.
63. Lee WJ, Park KH, Sohn MY, et al. Ultraviolet B irradiation increases the expression of inflammatory cytokines in cultured sebocytes. J Dermatol. 2013;40(12):993–997. doi: 10.1111/1346-8138.12330.
64. Araviiskaia E, Berardesca E, Bieber T, et al. The impact of airborne pollution on skin. J Eur Acad Dermatol Venereol. 2019;33(8): 1496–1505. doi: 10.1111/jdv.15583.
65. Cordain L, Lindeberg S, Hurtado M, et al. Acne vulgaris: a disease of Western civilization. Arch Dermatol. 2002;138(12): 1584–1590. doi: 10.1001/archderm.138.12.1584.
66. Phanse-Gupte SR, Khadilkar VV, Khadilkar AV. Clinical features and endocrine profile of Laron syndrome in Indian children. Indian J Endocrinol Metab. 2014;18(6):863–867. doi: 10.4103/2230-8210.140236.
67. Klinger B, Anin S, Silbergeld A, et al. Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome. Clin Endocrinol (Oxf). 1998;48(1):81–78. doi: 10.1046/j.1365-2265.1998.00356.x.
68. Paller AS, Mancini AJ. Hurwitz Clinical Pediatric Dermatology E-Book: A Textbook of Skin Disorders of Childhood and Adolescence. 5th ed. Elsevier Health Sciences; 2015. p. 176.
69. Самцов А.В., Аравийская Е.Р. Федеральные клинические рекомендации по ведению больных акне. М.: Российское общество дерматовенерологов и косметологов; 2013.
70. Nast A, Dreno B, Bettoli V, et al. European evidence-based (S3) guideline for the treatment of acne — update 2016 — short version. J Eur Acad Dermatol Venereol. 2016;30(8):1261–1268. doi: 10.1111/jdv.13776.
71. Jansen T, Burgdorf WH, Plewig G. Pathogenesis and treatment of acne in childhood. Pediatr Dermatol. 1997;14(1):17–21. doi: 10.1111/j.1525-1470.1997.tb00420.x.
72. Piggott CDS, Eichenfield LF, Lucky AW. Acne in children. In: Shalita AR, Del Rosso JQ, Webster GF, eds. Acne Vulgaris. New York, NY: Informa Healthcare; 2011. pp. 182–197.
73. Anane S, Chtourou O, Bodemer C, Kharfi M. Malassezia folliculitis in an infant. Med Mycol Case Rep. 2013;2:72–74. doi: 10.1016/j.mmcr.2013.02.005.
74. Antoniou C, Dessinioti C, Stratigos AJ, et al. Clinical and therapeutic approach to childhood acne: an update. Pediatr Dermatol. 2009;26(4):373–380. doi: 10.1111/j.1525-1470.2009.00932.x.
75. Oranje AP, Al-Mutairi N, Shwayder T. Practical Pediatric Dermatology: Controversies in Diagnosis and Treatment. Springer International Publishing; 2016. p. 64.
76. Serna-Tamayo C, Janniger CK, Micali G, Schwartz RA. Neonatal and Infantile Acne Vulgaris: An Update. Cutis. 2014;94(1):13–16.
77. Poole CN, McNair V. Infantile Acne. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020. Available online: https://www.ncbi.nlm.nih.gov/books/NBK541124/. Accessed on June 22, 2020.
78. Admani S, Barrio VR. Evaluation and treatment of acne from infancy to preadolescence. Dermatol Ther. 2013;26(6):462–466. doi: 10.1111/dth.12108.
79. Friedlander SF, Baldwin HE, Mancini AJ, et al. The acne continuum: an age-based approach to therapy. Semin Cutan Med Surg. 2011;30(3 Suppl):S6–11. doi: 10.1016/j.sder.2011.07.002.
80. Mann MW, Ellis SS, Mallory SB. Infantile acne as the initial sign of an adrenocortical tumor. J Am Acad Dermatol. 2007; 56(2 Suppl):S15–S18. doi: 10.1016/j.jaad.2006.04.028.
81. Samycia M, Lam JM. Infantile acne. CMAJ. 2016;188(17–18): E540. doi: 10.1503/cmaj.160139.
82. Cantatore-Francis JL, Glick SA. Childhood acne: evaluation and management. Dermatol Ther. 2006;19(4):202–209. doi: 10.1111/j.1529-8019.2006.00076.x.
83. Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-Based Recommendations for the Diagnosis and Treatment of Pediatric Acne. Pediatrics. 2013;131(Suppl 3):S163–S186. doi: 10.1542/peds.2013-0490b.
84. Davern J, O’Donnell AT. Stigma predicts health-related quality of life impairment, psychological distress, and somatic symptoms in acne sufferers. PLoS One. 2018;13(9):e0205009. doi: 10.1371/journal.pone.0205009.
85. Cunliffe WJ. The acnes. London: Martin Dunitz Ltd.; 1989.
86. Bagatin E, Freitas THP, Rivitti-Machado MC, et al. Adult female acne: a guide to clinical practice. An Bras Dermatol. 2019;94(1): 62–75. doi: 10.1590/abd1806-4841.20198203.
87. Collier CN, Harper JC, Cantrell WC, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008;58(1): 56–59. doi: 10.1016/j.jaad.2007.06.045.
88. Tan AU, Schlosser BJ, Paller AS. A review of diagnosis and treatment of acne in adult female patients. Int J Womens Dermatol. 2017;4(2):56–71. doi: 10.1016/j.ijwd.2017.10.006.
89. Dreno B, Thiboutot D, Layton AM, et al. Large-scale international study enhances understanding of an emerging acne population: adult females. J Eur Acad Dermatol Venereol. 2015;29(6): 1096–1106. doi: 10.1111/jdv.12757.
90. Круглова Л.С., Грязева Н.В., Талыбова А.М. Симптомокомплекс постакне: методы профилактики и терапии // Клиническая дерматология и венерология. — 2020. — Т. 19. — № 5. — С. 622–629. doi: 10.17116/klinderma202019051622.
91. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009; 60(5 Suppl):S1–S50. doi: 10.1016/j.jaad.2009.01.019.
92. Thielitz A, Abdel-Naser MB, Fluhr JW, et al. Topical retinoids in acne — an evidence-based overview. J Dtsch Dermatol Ges. 2008;6(12):1023–1031. doi: 10.1111/j.1610-0387.2008.06741.x.
93. Czernielewski J, Michel S, Bouclier M, et al. Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne. J Eur Acad Dermatol Venereol. 2001;15(Suppl 3):5–12. doi: 10.1046/j.0926-9959.2001.00006.x.
94. Thiboutot D, Dreno B, Gollnick H, et al. A Call to Limit Antibiotic Use in Acne. J Drugs Dermatol. 2013;12(12):1331–1335.
95. Rosen T. Antibiotic resistance: an editorial review with recommendations. J Drugs Dermatol. 2011;10(7):724–733.
96. Kircik LH. Re-evaluating treatment targets in acne vulgaris: adapting to a new understanding of pathophysiology. J Drugs Dermatol. 2014;13(6):s57–s60.
97. Nast A, Dreno B, Bettoli V, et al. European Evidence-based (S3) Guidelines for the Treatment of Acne. J Eur Acad Dermatol Venereol. 2012;26(Suppl. 1):1–29. doi: 10.1111/j.1468-3083.2011.04374.x.
98. Thiboutot DM, Dreno B, Abanmi A, et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2 Suppl 1):S1-S23.e1. doi: 10.1016/j.jaad.2017.09.078.
99. Sacchidanand SA, Lahiri K, Godse K, et al. Synchronizing Pharmacotherapy in Acne with Review of Clinical Care. Indian J Dermatol. 2017;62(4):341–357. doi: 10.4103/ijd.IJD_41_17.
100. Leyden JJ, Preston N, Osborn C, Gottschalk RW. In-vivo Effectiveness of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel on Antibiotic-sensitive and Resistant Propionibacterium Acnes. J Clin Aesthet Dermatol. 2011;4(5): 22–26.
101. Tan J, Gollnick HP, Loesche C, et al. Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients. J Dermatolog Treat. 2011;22(4):197–205. doi: 10.3109/09546631003681094.
102. Zuliani T, Khammari A, Chaussy H, et al. Ex vivo demonstration of a synergistic effect of Adapalene and benzoyl peroxide on inflammatory acne lesions. Exp Dermatol. 2011;20(10):850–853. doi: 10.1111/j.1600-0625.2011.01339.x.
103. Kircik LH. Synergy and its clinical reievance in topical acne therapy. J Clin Aesthet Dermatol. 2011;4(11):30–33.
104. Filo-Rogulska M, Wcislo-Dziadecka D, Brzezinska-Wcislo L. Neonatal and infantile acne — etiopathogenesis, clinical presentation and treatment possibilities. Post N Med. 2018;XXXI(1A):45–48. doi: 10.25121/PNM.2018.31.1A.45.
105. Oon HH, Wong SN, Aw DCW, et al. Acne Management Guidelines by the Dermatological Society of Singapore. J Clin Aesthet Dermatol. 2019;12(7):34–50.
106. Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol. 1998;139(Suppl 52):8–11. doi: 10.1046/j.1365-2133.1998.1390s2008.x.
107. Eichenfield LF, Draelos Z, Lucky AW, et al. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene-benzoyl peroxides. J Drugs Dermatol. 2013; 12(6):611–618.
108. Sittart JA, da Costa A, Mulinari-Brenner F, et al. Multicenter study for efficacy and safety evaluation of a fixeddose combination gel with adapalen 0.1% and benzoyl peroxide 2.5% Epiduo® for the treatment of acne vulgaris in Brazilian population. An Bras Dermatol. 2015; 90(6 Suppl 1):1–16. doi: 10.1590/abd1806-4841.20153969.
109. Gollnick HPM, Funke G, Kors C, et al. Efficacy of adapalene/ benzoyl peroxide combination in moderate inflammatory acne and its impact on patient adherence. J Dtsch Dermatol Ges. 2015; 13(9):969. doi: 10.1111/ddg.12613.
110. Dreno B, Bissonnette R, Gagne-Henley A, et al. Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison. Am J Clin Dermatol. 2018;19(2): 275–286. doi: 10.1007/s40257-018-0352-y.
111. Bettoli V, Borghi A, Zauli S, et al. Maintenance Therapy for Acne Vulgaris: Efficacy of a 12-Month Treatment with Adapalene-Benzoyl Peroxide after Oral Isotretinoin and a Review of the Literature. Dermatology. 2013;227(2):97–102. doi: 10.1159/000350820.
112. Poulin Y, Sanchez NP, Bucko A, et al. A 6-month maintenance therapy with adapalene-benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial. Br J Dermatol. 2011; 164(6):1376–1382. doi: 10.1111/j.1365-2133.2011.10344.x.
113. Goldsmith LA, Bolognia JL, Callen JP, et al. American Academy of Dermatology. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol. 2004;50(6):900–906. doi: 10.1016/j.jaad.2004.02.012.
114. Miller IM, Echeverria B, Torrelo A, Jemec GBE. Infantile Acne Treated with Oral Isotretinoin. Pediatr Dermatol. 2012;30(5): 513–518. doi: 10.1111/pde.12069.
115. Chinese Guidelines for the Management of Acne Vulgaris: 2019 Update#. Int J Dermatol Venereol. 2019;2(3):129–138. doi: 10.1097/JD9.0000000000000043.
116. Lam C, Zaenglein AL. Contraceptive use in acne. Clin Dermatol. 2014;32(4):502–515. doi: 10.1016/j.clindermatol.2014.05.002.
117. Araviiskaia E, Dreno B. The role of topical dermocosmetics in acne vulgaris. J Eur Acad Dermatol Venereol. 2016;30(6):926–935. doi: 10.1111/jdv.13579.
118. Araviiskaia E, Lopez Estebaranz JL, Pincelli C. Dermocosmetics: beneficial adjuncts in the treatment of acne vulgaris. J Dermatol Treat. 2019; 1–8. doi: 10.1080/09546634.2019.1628173.
119. Chim C. Acne Vulgaris. ACSAP; 2016. Book 2: Dermatologic Care.
Рецензия
Для цитирования:
Аравийская Е.Р., Мурашкин Н.Н., Намазова-Баранова Л.С., Иванов Р.А. Современные представления о патогенезе, особенностях клинической картины, диагностике и терапевтической тактике вульгарных акне у детей и подростков. Вопросы современной педиатрии. 2020;19(6):408-419. https://doi.org/10.15690/vsp.v19i6.2141
For citation:
Araviiskaia E.R., Murashkin N.N., Namazova-Baranova L.S., Ivanov R.A. Modern Outlooks on Pathogenesis, Clinical Picture, Diagnosis and Management of Acne Vulgaris in Children and Adolescents. Current Pediatrics. 2020;19(6):408-419. (In Russ.) https://doi.org/10.15690/vsp.v19i6.2141
Просмотров: 1673
Послать статью по эл. почте 
